Search results
Results from the WOW.Com Content Network
AIM ImmunoTech Inc. (NYSE: AIM) shares are trading higher on Tuesday after the company announced the receipt of "statistically significant positive survival results" in pancreatic cancer from an ...
The incumbent Board has controlled AIM for almost nine years since 2016 and failed epically, and dating back even further, Equels (16 years on the Board), Mitchell (26 years on the Board) and Appelrouth (13 years on the Board and consulting) each played a central role in leading AIM down the path of failure and value destruction. 4 When given ...
Shares of thinly-traded microcap AIM ImmunoTech Inc. (NYSE: AIM ) are trading sharply higher after the company announced the Department of Defense granted a four-year, $6.42 million "Breakthrough ...
AIM ImmunoTech Inc (NYSE: AIM) has announced the presentation of positive data from a Phase 1 study of Ampligen in metastatic triple-negative breast cancer. The pre-determined primary efficacy ...
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. [2] Founded in 1990, the company has twenty-three employees. [3]
It was first synthesized in the 1970s and is manufactured by AIM ImmunoTech (formerly known as Hemispherx Biopharma). [2] Although Ampligen was initially cleared for use in Canada in 1997, [3] and obtained orphan drug status for treatment of ME/CFS in the European Union in 2000, it is approved for use only in Argentina.
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.